Status:
UNKNOWN
The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel
Lead Sponsor:
Gottfried Maya
Conditions:
Metastatic Lung Cancer
Metastatic Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer. One of the main plasma prot...
Detailed Description
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer. One of the m...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- patients with metastatic cancer from lung, breast, gastric, prostate, and bladder origin
- patients must be treated with docetaxel based chemotherapy
- patients must sign an informed consent form
- Exclusion Criteria
- patients with metastatic cancer other than lung, breast, gastric, prostate, and bladder origin
- patients treated with chemotherapy other than docetaxel
- patients that did not sign an informed consent form
Exclusion
Key Trial Info
Start Date :
April 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2018
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01814150
Start Date
April 1 2013
End Date
April 1 2018
Last Update
March 25 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Oncology, Meir Medical Center
Kfar Saba, Israel